HWPC(SH:688799) Shang Hai Zheng Quan Bao·2025-08-30 01:57Group 1 - The company has approved an increase in the comprehensive credit limit to a total of RMB 120 million for 2025, up from the previous limit of RMB 86 million [4][5] - The additional credit limit of RMB 34 million is intended to support the operational needs of the company and its subsidiaries [4] - The credit facilities will include various types of loans and financial instruments, subject to the actual approval by financial institutions [5] Group 2 - The company will participate in a collective performance briefing for the innovative drug industry on September 16, 2025, to discuss its semi-annual results [7][8] - Investors can submit questions for the briefing from September 9 to September 15, 2025, through the designated online platform [10] - The briefing will be conducted in an interactive text format, allowing for real-time communication with investors [8][9] Group 3 - The company held its fourth board meeting on August 28, 2025, where several key resolutions were passed, including the approval of the semi-annual report [16][19] - The board meeting was attended by all seven directors, ensuring compliance with legal and regulatory requirements [15] - The resolutions included the approval of the special report on the management and actual use of raised funds [19][31]